XML 32 R21.htm IDEA: XBRL DOCUMENT v3.22.2.2
Revenues (Tables)
 9 Months Ended
Sep. 30, 2022
Revenue from Contract with Customer [Abstract]  
Schedule of Disaggregation of Revenue
Revenues consisted of the following (in thousands):
Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
Product revenues:
Gross product revenues$496,141 $357,462 $1,427,451 $1,051,871 
Discounts and allowances(129,659)(94,345)(403,627)(277,294)
Net product revenues366,482 263,117 1,023,824 774,577 
Collaboration revenues:
License revenues34,384 49,694 123,977 116,862 
Collaboration services revenues10,872 15,612 39,344 92,391 
Total collaboration revenues45,256 65,306 163,321 209,253 
Total revenues$411,738 $328,423 $1,187,145 $983,830 
Net product revenues by product were as follows (in thousands):
Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
CABOMETYX$361,385 $259,791 $1,003,356 $759,000 
COMETRIQ5,097 3,326 20,468 15,577 
Net product revenues$366,482 $263,117 $1,023,824 $774,577 
Schedule of Concentration Risks
The percentage of total revenues by customer who individually accounted for 10% or more of our total revenues were as follows:
Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
Affiliates of McKesson Corporation18 %15 %18 %15 %
Affiliates of CVS Health Corporation19 %16 %17 %15 %
Affiliates of AmerisourceBergen Corporation18 %16 %16 %14 %
Ipsen Pharma SAS8 %12 %11 %17 %
Accredo Health, Incorporated11 %9 %10 %8 %
The percentage of trade receivables by customer who individually accounted for 10% or more of our trade receivables were as follows:
September 30, 2022December 31, 2021
Affiliates of McKesson Corporation23 %10 %
Ipsen Pharma SAS21 %50 %
Affiliates of AmerisourceBergen Corporation20 %11 %
Affiliates of CVS Health Corporation15 %9 %
Schedule of Revenues Disaggregated by Geographic Region
Revenues by geographic region were as follows (in thousands):
Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
U.S.$369,480 $266,436 $1,033,160 $783,583 
Europe34,818 38,095 131,585 162,822 
Japan7,440 23,892 22,400 37,425 
Total revenues$411,738 $328,423 $1,187,145 $983,830 
Schedule of Activities and Ending Reserve Balances for Significant Categories of Discounts and Allowances
The activities and ending reserve balances for each significant category of discounts and allowances, which constitute variable consideration, were as follows (in thousands):
Chargebacks, Discounts for Prompt Payment and Other
Other Customer Credits/Fees and Co-pay Assistance
Rebates
Total
Balance at December 31, 2021
$14,625 $8,875 $24,825 $48,325 
Provision related to sales made in:
Current period261,143 36,847 105,280 403,270 
Prior periods632 (169)(106)357 
Payments and customer credits issued(255,002)(32,765)(98,996)(386,763)
Balance at September 30, 2022
$21,398 $12,788 $31,003 $65,189 
Schedule of Other Assets and Other Liabilities Contract assets and liabilities were as follows (in thousands):
September 30, 2022December 31, 2021
Contract assets (1)
$364 $1,665 
Contract liabilities:
Current portion (2)
$6,932 $7,814 
Long-term portion (3)
6,491 8,739 
Total contract liabilities$13,423 $16,553 
____________________
(1)    Presented in other long-term assets in the accompanying Condensed Consolidated Balance Sheets.
(2)    Presented in other current liabilities in the accompanying Condensed Consolidated Balance Sheets.
(3)    Presented in the long-term portion of deferred revenues in the accompanying Condensed Consolidated Balance Sheets